

UNDERSTANDING REGARDING  
ARTICLE 2 OF ANNEX 26-A ON TRANSPARENCY AND PROCEDURAL FAIRNESS  
FOR PHARMACEUTICAL PRODUCTS AND MEDICAL DEVICES

February 4, 2016

The Governments of the United States of America and the Republic of Peru (individually a “Party” and collectively the “Parties”) have reached the following understanding concerning Annex 26-A on Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices contained in Chapter 26 (Transparency and Anti-Corruption) of the Trans-Pacific Partnership Agreement signed this day:


The Parties recognize that with regard to Article 2 (Principles) of Annex 26-A, it is understood that “high-quality healthcare” does not refer to specific final outcomes in a Party’s healthcare system, including the selection of specific pharmaceutical products.

FOR THE GOVERNMENT OF THE  
UNITED STATES OF AMERICA:



---

FOR THE GOVERNMENT OF THE  
REPUBLIC OF PERU:



---